Ultragenyx Pharmaceutical Inc. (RARE) earnings
RARE earnings moved a median of -0.08% by the close. Quarterly and annual RARE reports and results, each read against the price at its own news timestamp. Back to the RARE overview →
29 measured RARE earnings events.
Where these RARE earnings landedvs 29 measured RARE earnings reactions
| Middle 50% of RARE earnings reactions | -3.88% to +1.83% |
|---|---|
| Median reaction (to close) | -0.08% |
| Measured reactions | 29 |
Point-in-time · zero look-ahead
Half of the 29 RARE earnings events with a measured close landed between -3.88% and +1.83%; 48% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Form 10-Q Ultragenyx Pharmaceutica For: Jun 30 | SEC filing · Form 10-Q | -4.99% | -10.84% | |
| Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update | Press release | -4.99% | -10.84% | |
| Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update | Press release | +0.93% | -2.99% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 | SEC filing · Form 10-Q | +1.24% | +0.08% | |
| Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update | Press release | +1.24% | +0.08% | |
| Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update | Press release | +1.43% | +0.21% | |
| Form 10-K Ultragenyx Pharmaceutica For: Dec 31 | SEC filing · Form 10-K | -0.22% | +6.96% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Sep 30 | SEC filing · Form 10-Q | +5.45% | +10.28% | |
| Ultragenyx Reports Third Quarter 2025 Financial Results and Corporate Update | Press release | +5.45% | +10.28% | |
| Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update | Press release | -1.17% | +0.17% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Jun 30 | SEC filing · Form 10-Q | -2.19% | -1.51% | |
| Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update | Press release | -0.36% | -2.97% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 | SEC filing · Form 10-Q | -4.57% | -6.28% | |
| Ultragenyx Reports First Quarter 2025 Financial Results and Corporate Update | Press release | -4.57% | -6.28% | |
| Ultragenyx to Host Conference Call for First Quarter 2025 Financial Results and Corporate Update | Press release | -2.42% | -0.08% | |
| Form 10-K Ultragenyx Pharmaceutica For: Dec 31 | SEC filing · Form 10-K | -0.18% | +0.23% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Sep 30 | SEC filing · Form 10-Q | +0.06% | -3.88% | |
| Ultragenyx Reports Third Quarter 2024 Financial Results and Corporate Update | Press release | +0.06% | -3.88% | |
| Ultragenyx to Host Conference Call for Third Quarter 2024 Financial Results and Corporate Update | Press release | +0.77% | -0.88% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Jun 30 | SEC filing · Form 10-Q | -3.69% | +6.52% | |
| Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update | Press release | -3.69% | +6.52% | |
| Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update | Press release | -0.37% | -1.54% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 | SEC filing · Form 10-Q | -0.26% | -4.75% | |
| Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update | Press release | -0.26% | -4.75% | |
| Ultragenyx to Host Conference Call for First Quarter 2024 Financial Results and Corporate Update | Press release | -1.00% | +0.18% | |
| Form 10-K Ultragenyx Pharmaceutica For: Dec 31 | SEC filing · Form 10-K | -0.21% | +1.83% | |
| Form 10-Q Ultragenyx Pharmaceutica For: Sep 30 | SEC filing · Form 10-Q | +4.00% | +5.54% | |
| Ultragenyx Reports Third Quarter 2023 Financial Results and Corporate Update | Press release | +4.00% | +5.54% | |
| Ultragenyx to Host Conference Call for Third Quarter 2023 Financial Results and Corporate Update | Press release | -3.42% | -5.56% |
Keep exploring
More RARE: analyst actions → · SEC filings → · RARE overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Quotient Limited - Ordinary Shares (QTNT) | 982 | -0.13% | 42% |
| PDL BIOPHARMA (PDLI) | 967 | 0.00% | 46% |
| QuidelOrtho Corporation (QDEL) | 965 | +0.02% | 50% |
| Recro Pharma, Inc. (REPH) | 965 | 0.00% | 43% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.